Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALMS Stock Forecast 2026-2027
$24.34
Current Price
$3.03B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALMS Price Targets
+105.4%
To High Target of $50.00
+43.8%
To Median Target of $35.00
+31.5%
To Low Target of $32.00
ALMS Price Momentum
+33.9%
1 Week Change
+115.2%
1 Month Change
+214.9%
1 Year Change
+149.4%
Year-to-Date Change
-2.0%
From 52W High of $24.83
+781.9%
From 52W Low of $2.76
📊 TOP ANALYST CALLS
Did ALMS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alumis is one of their latest high-conviction picks.
Latest ALMS Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, ALMS has a bullish consensus with a median price target of $35.00 (ranging from $32.00 to $50.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $24.34, the median forecast implies a 43.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Thomas Smith at Leerink Partners, suggesting a 31.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALMS Analyst Ratings
8
Buy
0
Hold
0
Sell
ALMS Price Target Range
Low
$32.00
Average
$35.00
High
$50.00
Current: $24.34
Latest ALMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $40.00 |
| Jan 7, 2026 | Leerink Partners | Thomas Smith | Outperform | Maintains | $32.00 |
| Jan 7, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $33.00 |
| Jan 7, 2026 | Guggenheim | Yatin Suneja | Buy | Maintains | $32.00 |
| Jan 6, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $39.00 |
| Dec 18, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $20.00 |
| Aug 15, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $22.00 |
| Aug 14, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $14.00 |
| Jul 25, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $14.00 |
| Jul 25, 2025 | Wells Fargo | Derek Archila | Overweight | Initiates | $17.00 |
| Jun 10, 2025 | Guggenheim | Yatin Suneja | Buy | Reinstates | $18.00 |
| May 15, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $25.00 |
| Apr 30, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $14.00 |
| Apr 22, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Mar 20, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $N/A |
| Mar 11, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
Alumis Inc. (ALMS) Competitors
The following stocks are similar to Alumis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alumis Inc. (ALMS) Financial Data
Alumis Inc. has a market capitalization of $3.03B with a P/E ratio of 0.2x. The company generates $22.12M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -22.5% quarter-over-quarter, while maintaining an operating margin of -5,372.3% and return on equity of -66.9%.
Valuation Metrics
Market Cap
$3.03B
Enterprise Value
$1.97B
P/E Ratio
0.2x
PEG Ratio
0.0x
Price/Sales
124.6x
Growth & Margins
Revenue Growth (YoY)
-22.5%
Gross Margin
N/A
Operating Margin
-5,372.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+14.9%
Current Ratio
6.0x
Debt/Equity
9.8x
ROE
-66.9%
ROA
-61.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alumis Inc. (ALMS) Business Model
About Alumis Inc.
What They Do
Develops innovative therapies for autoimmune diseases.
Business Model
Alumis Inc. generates revenue through the research, development, and commercialization of novel therapeutic solutions for autoimmune diseases. The company focuses on addressing unmet medical needs by leveraging advanced scientific techniques and collaborating with leading researchers to create targeted treatments.
Additional Information
Alumis Inc. is committed to fostering innovation in the biopharmaceutical sector, aiming to improve patient outcomes and the quality of life for those suffering from complex health issues. The company's distinct methodology enhances the diversity of treatment options available in the healthcare market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
221
CEO
Mr. Martin Babler Ph.D.
Country
United States
IPO Year
N/A
Website
www.alumis.comAlumis Inc. (ALMS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Jan 07, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Alumis Inc. (Nasdaq: ALMS) has priced an upsized public offering of 17.65 million shares at $17.00 each, aimed at funding its development of targeted therapies for immune-mediated diseases.
Why It Matters
Alumis Inc.'s upsized public offering indicates strong market interest but may dilute existing shares. Pricing at $17.00 could impact stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alumis shares surged 95% following positive results from two phase III studies of envudeucitinib for plaque psoriasis, achieving all primary endpoints and demonstrating significant skin clearance.
Why It Matters
Alumis' share surge indicates strong investor confidence in envudeucitinib's potential market success, which could lead to increased revenue and growth opportunities for the company.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Alumis Inc. closed an upsized public offering of 20,297,500 shares at $17.00 each, including the full exercise of an underwriters' option for 2,647,500 additional shares.
Why It Matters
Alumis Inc. raised significant capital through a public offering, enhancing its financial position for R&D. This could signal growth potential and impact stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alumis Inc. shares jumped 95% after positive Phase 3 results for envudeucitinib in psoriasis. The company also announced a $175 million public offering to support further development.
Why It Matters
Alumis Inc.'s stock surge reflects strong Phase 3 drug results, indicating potential market success. The $175 million offering signals confidence in ongoing development and future growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Investors are reacting positively to envudeucitinib's successful Phase 3 trial for oral TYK2 psoriasis and Alumis' plans to raise new capital.
Why It Matters
Positive Phase 3 results for envudeucitinib in psoriasis could boost its market appeal, while Alumis' capital raise may indicate growth potential, impacting stock valuations.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Alumis reported that its experimental pill achieved the main goal in two late-stage studies for a type of skin disease, indicating potential progress in their treatment development.
Why It Matters
Alumis's successful late-stage studies for its experimental pill may lead to FDA approval, potentially boosting its market value and attracting investor interest in the biotech sector.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About ALMS Stock
What is Alumis Inc.'s (ALMS) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Alumis Inc. (ALMS) has a median price target of $35.00. The highest price target is $50.00 and the lowest is $32.00.
Is ALMS stock a good investment in 2026?
According to current analyst ratings, ALMS has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALMS stock?
Wall Street analysts predict ALMS stock could reach $35.00 in the next 12 months. This represents a 43.8% increase from the current price of $24.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alumis Inc.'s business model?
Alumis Inc. generates revenue through the research, development, and commercialization of novel therapeutic solutions for autoimmune diseases. The company focuses on addressing unmet medical needs by leveraging advanced scientific techniques and collaborating with leading researchers to create targeted treatments.
What is the highest forecasted price for ALMS Alumis Inc.?
The highest price target for ALMS is $50.00 from at , which represents a 105.4% increase from the current price of $24.34.
What is the lowest forecasted price for ALMS Alumis Inc.?
The lowest price target for ALMS is $32.00 from Thomas Smith at Leerink Partners, which represents a 31.5% increase from the current price of $24.34.
What is the overall ALMS consensus from analysts for Alumis Inc.?
The overall analyst consensus for ALMS is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ALMS stock price projections?
Stock price projections, including those for Alumis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 5:39 AM UTC